| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8690546 | Pediatric Neurology | 2017 | 23 Pages |
Abstract
Our results suggest that tacrolimus is a promising agent for children with refractory myasthenia gravis. Randomized clinical trials are needed to confirm the observation.
Related Topics
Life Sciences
Neuroscience
Developmental Neuroscience
Authors
Chanchan Liu, Mengcui Gui, Yayun Cao, Jing Lin, Yue Li, Suqiong Ji, Bitao Bu,